Cardiotoxicity in kids with relapsed AML and what it means for their hearts
Official title: Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications
Funded at University of Pennsylvania · NIH-11367516 · Data updated 2026-11-12
A study tracking how chemotherapy for relapsed pediatric AML affects heart health over time and what that means for long-term wellbeing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 15, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $302,471 |
| NIH project number | 5R01HL164925-05 |
| Project ID | NIH-11367516 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and adolescents (roughly under 18) with relapsed or refractory AML who are undergoing chemotherapy.
✕Less likely to help
Patients not experiencing relapse or not receiving the treatments studied would not directly benefit from this research.
What this research studies
This project follows children and adolescents with relapsed AML to document how often heart-related side effects occur, how severe they are, and how the heart recovers after treatment. It aims to map the timing and progression of cardiotoxicity during and after relapse therapy, using patient medical records and follow-up assessments. By understanding the natural history of these heart effects, doctors can tailor treatments to protect heart health while aiming to control leukemia.
Why it matters
Potential benefit: If successful, the study could lead to better strategies to prevent or manage cardiotoxicity, improving long-term heart health for kids after AML treatment.
How similar studies have gone: Previous work shows cardiotoxicity is a common issue with pediatric AML therapy, but long-term data during relapse are limited and this study seeks to fill that gap.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Getz, Kelly Diringer — University of Pennsylvania
- Study coordinator: Getz, Kelly Diringer
Related research
Other NIH-funded projects on the same topics.
-
Understanding Heart Problems from Chemotherapy in Children with Relapsed Leukemia
This project aims to better understand how chemotherapy for relapsed acute myeloid leukemia (AML) affects the hearts of children and adolescents.
-
Investigating heart-related side effects in children with relapsed acute myeloid leukemia
This study is looking at how heart problems can affect kids who have had a relapse of acute myeloid leukemia after their chemotherapy, so we can better understand and manage these side effects during their treatment.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.